{"entity":{"id":"nct06800313","kind":"trial","name":"Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer","aka":[],"tldr":"A phase 1/2 trial of JNJ-101556143 Formulation 1 in prostate cancer, run by Janssen Research & Development, LLC, now recruiting.","summary":"Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer is a phase 1/2 interventional study registered as NCT06800313 by Janssen Research & Development, LLC, with 190 participants planned, started 2025-02-06 and due to reach its primary completion in 2028-07-11. Interventions recorded: JNJ-101556143 Formulation 1, JNJ-101556143 Formulation 2 and JNJ-101556143 Formulation 3.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06800313","url":"https://clinicaltrials.gov/study/NCT06800313"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["johnson-johnson"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06800313","phase":"1/2","setting":"Phase 1/2 Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer","sponsor":"Janssen Research & Development, LLC","enrolled":190,"outcomes":[]},"route":"/trials/nct06800313/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"company":[{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"}]}}